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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2015, KaohsiuAbstract Preeclampsia (PE) and intrauterine growth restriction (IUGR) are still among themost
commonly researched titles in perinatology. To shed light on their etiology, new prevention and
treatment strategies are the major targets of studies. In this study, we aimed to investigate the
relation between gene polymorphism of one of the products of trophoblasts, pregnancy-
associated plasma protein A (PAPP-A) and PE/IUGR.A total of 147 women (IUGR, nZ 61; PE,
nZ 47; IUGR þ PE, nZ 37; eclampsia, nZ 2) were compared with 103 controls with respect
to the sequencing of exon 14 of the PAPP-A gene to detect (rs7020782) polymorphism. Genotypes
“AA” and “CC” were given in the event of A or C allele homozygosity and “AC” in A and C allele
heterozygosity. Our findings revealed that the rate of AA, CC homozygotes, and AC heterozy-
gotes did not differ between groups. Moreover, there was no difference in the distribution of
PAPP-A genotypes among the patients with IUGR, PE, IUGR þ PE, or eclampsia. Finally, birth
weight, rate of the presence of proteinuria, and total protein excretion on 24-hour urine were
similar in the subgroups of AA, AC, and CC genotypes in the study group. Our study demonstrated
no association between PAPP-A gene rs7020782 polymorphism and PE/IUGR.
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Although several associated theories have been proposed
about the underlying mechanisms of preeclampsia (PE), a
disease generally defined as pregnancy-induced hyperten-
sion with albuminuria arising after the 20th week of gesta-
tion, its etiology has yet to be definitively defined [1].
Today, PE is thought to result from a composition of
immunologic, inflammatory, nutritional, and genetic fac-
tors that lead to the failure of the action of migratory
interstitial and endovascular trophoblast into the walls of
the spiral arterioles [2e4].
Intrauterine growth restriction (IUGR), affecting
w5e10% of pregnancies, is usually defined as the situation
when the fetus is below the 10th percentile on the curve of
weight for gestational age [5]. Maternal, fetal, placental,
and external factors combined with the genetically pre-
determined growth potential organize the normal fetal
growth, and failures of these factors result in IUGR and
associated disorders [6].
The insulin-like growth factors (IGFs) play a considerable
role in the growth of fetoplacental tissues throughout
gestation [7]. Six insulin-like growth factor binding proteins
(IGFBPs) organize IGF activities by escalating the half-life,
localization, and migration of IGFs in particular tissues
[7,8]. Pregnancy-associated plasma protein-A (PAPP-A), a
zinc-binding metalloproteinase, releases IGF1 by cleaving
the IGFBP-4/IGF 1 complex in order to modulate local IGF1
bioavailability [9]. Moreover, the potential of the differ-
ential regulation of decidual PAPP-A in arranging IGF 2
bioavaibility at the throphoblastedecidual interface re-
veals that maternal PAPP-A in the endometrial stroma and
the trophoblastic tissues may have an influence on
placental and fetal growth and development during im-
plantation and pregnancy [10,11].
Proper interference between maternal endometrium,
and trophoblastic and embryonic tissues is mandatory to
ensure successful pregnancy outcomes. The failures in the
processing of proteins such as PAPP-A, which may result in
defective placentation, may pose unfavorable situations
such as PE/IUGR. We performed this study to evaluate the
potential association between the gene polymorphism
(rs7020782) of PAPP-A and PE/IUGR.
Methods
This prospective study was conducted on 250 women who
presented for prenatal care between January 2010 and
December 2013 to the Gynecology and Obstetrics Depart-
ment of Ege University, Izmir, Turkey. The protocol of the
study was approved by the Ethics Committee for Human
Studies at Ege University, and informed consent was ob-
tained from all participants. The inclusion criterion was a
diagnosis of PE, IUGR, PE with IUGR, or eclampsia. Women
with multiple pregnancies and pregnancies with congenital
and chromosomal abnormalities were excluded from the
study. The control group consisted of patients with normal
blood pressure and an appropriate weight for gestational
age fetus.
PE was defined as a persistent systolic blood pressure of
140 mmHg and a diastolic blood pressure of 90 mmHg orhigher, taken at least 6 hours apart, after 20 weeks of
gestation in a previously normotensive patient. Proteinuria
was defined as urine protein concentration of  300 mg/dL
or 1þ on a urine dipstick in at least two random specimens
collected at least 4 hours apart [12]. Total protein excre-
tion on 24-hour urine was also calculated. IUGR was defined
as estimated fetal weight below the 10th percentile on ul-
trasound together with birth weight below the 10th
percentile of the standard growth curve [5]. Finally,
eclampsia was defined as the development of convulsions
and/or unexplained coma during pregnancy or postpartum
in patients with signs and symptoms of PE [13].
Genomic deoxyribonucleic acid (DNA) was isolated from
peripheral blood cells using standard techniques. Forward
50-GCACTTCGCATGTGAGAAAA-30 and reverse 50-GAGCT-
CAGCACCTGCACATA-30 were used in order to amplify the
region surrounding rs7020782 polymorphism in the PAPP-A
gene [10,14]. Polymerase chain reaction (PCR) was per-
formed in a 25-mL reaction mix containing 5 mL of extracted
DNA, 2.5 mL buffer (10 Taq Buffer with KCl), 2 mL MgCl2
(25mM), 1 mL dNTP (10mM), and 1.25 mL (10 pmol/mL) for-
ward and reverse primer 0.5 mL (5 U/mL) Taq-Polimerase,
and 11.5 mL distilled water. PCR conditions were as fol-
lows: 95C for 11 minutes, then 35 cycles of 95C for 30
seconds, 57C for 30 seconds, 72C for 30 seconds, followed
by extension at 72C for 5 minutes. PCR products were
visualized on a 2% agarose gel by electrophoresis and pu-
rified before cycle sequencing. All PCR products were
sequenced with the dye termination method using a DNA
sequencing kit (Perkin-Elmer, Foster City, CA, USA) and
analyzed using the ABI Prism 3100 sequence analyzer
(Applied Biosystems, Foster City, CA, USA). Genotypes “AA”
and “CC” labels were given in the event of A or C allele
homozygosity and “AC” in the event of A and C allele
heterozygosity.
Statistical analysis was performed with the SPSS version
11.0 statistical software package (SPSS Inc., Chicago, IL,
USA). KolmogoroveSmirnov test was used to detect normal
distribution. Continuous parameters were expressed as
mean  standard deviation when normally distributed.
Categorical results were expressed as percentages. For
comparisons, Chi-square, analysis of variance, Krus-
kaleWallis, and ManneWhitney U tests were used, where
appropriate.Results
A total of 147 women (61 IUGR, 47 PE, 37 IUGR þ PE, 2
eclampsia) were compared with 103 controls. Patients in
the study group delivered at earlier gestational ages and
had infants with significantly lower birth weights (Table 1).
The rate of AA, CC homozygotes, and AC heterozygotes did
not differ between study and control groups (p Z 0.966,
Chi-square test; Table 2).
Furthermore, there was no difference in the distribution
of PAPP-A genotypes among the patients with IUGR, PE,
IUGR þ PE, or eclampsia (pZ 0.942, Chi-square test; Table
3). Additionally, birth weight, rate of the presence of pro-
teinuria, and total protein excretion on 24-hour urine were
similar in the subgroups AA, AC, and CC genotypes in the
study group (Table 4).
Table 1 Characteristics of groups.
Study group
(n Z 147)
Control group
(n Z 103)
p
Age (y) 29.8  6.0 28.6  5.5 NS
Gravida 2.1  0.9 1.9  0.9 NS
Parity 0.7  0.6 0.9  0.6 NS
Body mass
index (kg/m2)
25.0  5.0 24.8  3.8 NS
Gestational
age at
delivery (wk)
34.9  3.2 38.1  2.6 < 0.001*
Birth weight (g) 1895  650 3163  647 < 0.001*
Data are presented as mean  SD.
* Statistically significant (ManneWhitney U test).
NS Z not significant; SD Z standard deviation.
Table 2 Distribution of PAPP-A genotypes in the study and
control groups.
AA AC CC Total
Study group 78 (53.1) 59 (40.1) 10 (6.8) 149 (100)
Control group 53 (51.5) 43 (41.7) 7 (6.8) 103 (100)
Data are presented as n (%).
Table 3 Distribution of PAPP-A genotypes among various
groups.
AA AC CC Total
IUGR 35 (57.4) 21 (34.4) 5 (8.2) 61 (100)
PE 24 (51.1) 20 (42.6) 3 (6.4) 47 (100)
IUGR þ PE 18 (48.6) 17 (45.9) 2 (5.4) 37 (100)
Eclampsia 1 (50) 1 (50) 0 (0) 2 (100)
Data are presented as n (%).
IUGR Z intrauterine growth restriction; PE Z preclampsia.
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The etiologies of PE and IUGR are multifactorial, with po-
tential variations in genes involved in placental develop-
ment, blood pressure regulation, or endothelial
functioning. The findings of recent investigations revealed
that some of the maternal polymorphisms includingTable 4 Features of AA, AC, and CC genotypes in the study gro
AA genotype
Birth weight (g) 1970  706
Presence of proteinuria 55.1
24-h urine protein (g/d) 3.06  3.07
Data are presented as mean  SD or (%).
ANOVA Z analysis of variance; SD Z standard deviation.
a Indicates ANOVA.
b Indicates Chi-square test.
c Indicates KruskaleWallis test.C-reactive protein gene, angiotensinogen gene, tumor ne-
crosis factor receptor gene, and vascular endothelial
growth factor family genes were related to higher risks of
PE occurrence [15e18]. However, this relation was not
distinct when examined in some variants of multidrug
resistance 1, interleukin-10 (G-1082A) promoter, and
endothelial nitric oxide synthase genes [19e21]. Like PE,
the association of some maternal gene polymorphisms and
IUGR were revealed in contemporary trials [22,23]. In a
well-designed study, maternal deletion allele of
angiotensin-converting enzyme gene was found to be
associated with fetal growth restriction [24]. Although not
confirmed in our study, these results indicate the prospect
that genetic factors may have important roles in PE and
IUGR pathogenesis.
The PAPP-A gene is located in chromosome 9q33.1 and
contains 22 exons [25]. The clinical importance of the
polymorphism of this gene was primarily searched in car-
diology studies and determined as an independent risk
factor for acute myocardial infarction [26]. Later, studies in
perinatal medicine analyzing other exons were conducted.
In one of the trials that aimed to evaluate PAPP-A poly-
morphisms in patients with risk pregnancies (preterm labor
and PE), exon 5 and exon 7 were examined, but no diver-
gence from the wild-types were detected [27]. In another
study, exon 2 and exon 6 were assessed, and significantly
higher frequency of Cys327Cys (rs2375498) polymorphism in
exon 2 were found in patients with PE [28].
To the best of our knowledge, our study represents the
primary data about the association of rs7020782 poly-
morphism in exon 14 of PAPP-A gene and IUGR/PE. This
variation was initially determined by Frosk et al [29], and
its relationship with ischemic cerebrovascular disease was
proved [30]. Additionally, some associationdalthough not
at a significant leveldwas determined in patients with
recurrent pregnancy loss [10]. According to our final data,
tyrosine/serine mutation (rs7020782 polymorphism in exon
14) does not seem to be a part of either PE or IUGR.
The effect of maternal serum PAPP-A levels on preg-
nancy outcomes was broadly studied. In a recently pub-
lished review, decreased serum levels in all trimesters were
found to be a risk factor for both PE and IUGR, whereas
some authors reported elevated third trimester levels in
preeclamptic pregnancies [31,32]. Although appearing as
one of the limitations of our study, these conflicting results
and the reported uncorrelation between PAPP-A poly-
morphism and serum PAPP-A levels prompted us to forego
performing a maternal serum PAPP-A analysis [10]. Theup.
AC genotype CC genotype p
1769  590 2067  455 0.161 a
62.1 60 0.714 b
5.71  5.82 6.15  2.60 0.107 c
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is another limitation. Multicentral studies may put forward
solutions, particularly with regard to the consequences of
the low frequency of this type of genetic variants.
PAPP-A is a product of growing trophoblasts and indi-
rectly induces aggression to the endometrium [33].
Although they have multifactorial underlying etiologies, PE
and IUGR are partly thought to be disorders of abnormal
early trophoblastic invasion. In this prospective study, we
included pregnant women with PE, IUGR, IUGR with
accompanying PE, or eclampsia, and evaluated the poten-
tial association of these disorders and PAPP-A gene
(rs7020782) polymorphism. However, our results showed no
relation. Future studies evaluating other gene poly-
morphisms may reveal more valuable data about PE and
IUGR.
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